- Three poster presentations showing
- the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.
- the reduction of the FastTM score in association with the beneficial effects of lanifibranor on liver histology and biologically relevant biomarkers, in patients with NASH and F2/F3 fibrosis.
- the identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with lanifibranor.
Daix (
The first abstract focuses on the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with NASH showing that they are independent of weight change. Based on the results of Inventiva’s NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH, the authors of the abstract analysed markers of cardiometabolic health in relation with the weight variation observed in patients treated with lanifibranor or on placebo. The treatment with lanifibranor showed beneficial effects on biomarkers of cardiometabolic health, including markers of lipid and glucose metabolism, insulin resistance and inflammation independent of weight change. These beneficial effects occurred in parallel with an increase of adiponectin levels demonstrating an improvement in adipose tissue health. These results provide further evidence that PPARγ-induced weight gain is associated with improved insulin sensitivity, i.e. is metabolically healthy and thus distinct from lifestyle-related weight gain.
The second abstract evaluates the beneficial effect of lanifibranor treatment on the FibroScan-aspartate aminotransferase (FastTM) score, a promising non-invasive test (NIT) for active NASH with significant fibrosis. Based on the data of the NATIVE trial, the authors evaluated the effect of treatment with lanifibranor on the FastTM score,the correlation between the histological and biomarker responses observed in patients with NASH and fibrosis F2/F3. The data showed that the treatment with lanifibranor induced a significant reduction of the FastTM score compared to placebo. This reduction under lanifibranor is associated with the histological endpoint ‘resolution of NASH and improvement of fibrosis’, and with the improvement in triglycerides, Apo-C3 and ferritin levels. These results highlight the potential of the FastTM score as a NIT to monitor disease progression and response to therapy.
The third abstract focuses on the identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with lanifibranor. The authors conducted an assessment of serum-based biomarkers from the Inventiva’s NATIVE Phase IIb clinical trial in order to identify biological signatures of the liver histological endpoints. The authors identified four biomarkers: baseline levels of adiponectin and ferritin, relative changes of MMP9 and transferrin at end of treatment, which combined into a score could predict the ‘NASH resolution and fibrosis improvement’ with a sensitivity of 70% and specificity of 95%. Four different biomarkers were identified as being predictive of the histological endpoint ‘NASH resolution without worsening of fibrosis’: baseline CK18-M65, absolute change of hyaluronate, relative changes of fructosamine and ALT at end of treatment, with a sensitivity of 79% and specificity of 89%. This exploratory assessment demonstrates that the combination of biomarker signatures allowed a non-invasive identification of histological response under lanifibranor treatment in NASH with a good diagnostic performance.
The details of the various presentations are as follows:
Abstract #1:
Abstract title: | "The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change" |
Publication number: | SAT119 |
Presentation type: | Poster presentation |
Authors: | |
Date: |
Abstract #2:
Abstract title: | "Lanifibranor therapy reduces the FibroScan-aspartate aminotransferase (FastTM) score associated with histological 'NASH resolution and improvement of fibrosis' and biomarker response" |
Publication number: | SAT120 |
Presentation type: | Poster presentation |
Authors: | |
Date: | |
Abstract #3:
Abstract title: | "Identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with Lanifibranor" |
Publication number: | SAT105 |
Presentation type: | Poster presentation |
Authors: | |
Date: | |
In addition, during the session « Critical reflection on landmark papers », taking place
About Inventiva
The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development.
The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
Contacts
VP of Global External Affairs media@inventivapharma.com +1 240 620 9175 | Aude Lepreux Media relations inventiva@brunswickgroup.com +33 1 53 96 83 83 | Westwicke, an Investor relations patti.bank@westwicke.com +1 415 513 1284 |
Important Notice
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinical programs and clinical trials, including recruitment for those trial, clinical trial data releases, including for part 1 of the Phase III clinical trial of lanifibranor in patients with NASH and two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozine, pipeline and preclinical and clinical development plans, milestone payments, royalties and product sales, future activities, expectations, plans, growth and prospects of
Please refer to the Universal Registration Document for the year ended
All information in this press release is as of the date of the release. Except as required by law,
Attachment
Inventiva - PR - EASL Abstracts - 06 09 2022
© OMX, source